Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Differential nuclear matrix protein expression in prostate cancers: correlation with pathologic stage

Y Lakshmanan1, E N Subong, A W Partin

  • 1James Buchanan Brady Urological Institute, Johns Hopkins Hospital, Baltimore, Maryland 21287-2101, USA.

The Journal of Urology
|March 21, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Preliminary report: Surgical outcomes following genitoplasty in children with moderate to severe genital atypia.

Journal of pediatric urology·2018
Same author

Use of the Prostate Health Index for detection of prostate cancer: results from a large academic practice.

Prostate cancer and prostatic diseases·2017
Same author

Prospective assessment of cosmesis before and after genital surgery.

Journal of pediatric urology·2016
Same author

Very-high-risk localized prostate cancer: definition and outcomes.

Prostate cancer and prostatic diseases·2013
Same author

Metastasis-free survival is associated with overall survival in men with PSA-recurrent prostate cancer treated with deferred androgen deprivation therapy.

Annals of oncology : official journal of the European Society for Medical Oncology·2013
Same author

Radical prostatectomy in men less than 50 years old.

Urologic oncology·2011

A novel protein, YL-1, was consistently found in aggressive prostate cancers. This nuclear matrix protein (NMP) may serve as a potential biomarker for predicting poor prognosis in localized prostate cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Nuclear Matrix Proteins (NMPs) exhibit tissue and cell-type specificity.
  • Several NMPs are explored as tumor markers in various cancers, including prostate, bladder, and kidney.
  • Understanding differential NMP expression is crucial for aggressive cancer characterization.

Purpose of the Study:

  • To characterize differential Nuclear Matrix Protein (NMP) expression in pathologically aggressive prostate cancers.
  • To identify potential protein markers associated with aggressive disease in localized prostate cancer.

Main Methods:

  • High-resolution two-dimensional gel electrophoresis and silver staining were employed.
  • Nuclear proteins were analyzed from 39 radical prostatectomy specimens.

Related Experiment Videos

  • Specimens were categorized into good, intermediate, and poor prognosis groups based on pathological grading (Gleason score, seminal vesicle/lymph node involvement, capsular penetration).

    • Main Results:

    • A specific 76 kD protein, designated YL-1, with an isoelectric range of 6.0-6.6, was consistently identified in 19 of 19 aggressive prostate cancers.
    • YL-1 was present in only 1 of 10 good prognosis cases.
    • Weak YL-1 expression was observed in 9 of 10 intermediate prognosis cases.

    Conclusions:

    • The expression of YL-1 appears correlated with aggressive prostate cancer in this preliminary study.
    • YL-1 shows potential as a biomarker for poor prognosis in clinically localized prostate cancer.
    • Further research is required to identify YL-1's precise identity and function for clinical application.